Zobrazeno 1 - 10
of 2 748
pro vyhledávání: '"acute myeloid leukemia (aml)"'
Autor:
Chenxu Zhu, Thomas Stiehl
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Acute myeloid leukemia (AML) is a stem cell-driven malignancy of the blood forming (hematopoietic) system. Despite of high dose chemotherapy with toxic side effects, many patients eventually relapse. The “7+3 regimen”, which consists of
Externí odkaz:
https://doaj.org/article/8f02ebadfb574c74abf0bc8a013179de
Publikováno v:
Current Oncology, Vol 31, Iss 10, Pp 6050-6060 (2024)
High-risk acute myeloid leukemia has been associated with a poor outcome. Hematopoietic stem cell transplantation (HSCT) represents the only curative option for eligible patients. Relapse after HSCT is a dramatic event with poor chances of survival.
Externí odkaz:
https://doaj.org/article/7d2a0582d8b74d75be61630a44c107e4
Publikováno v:
Alexandria Journal of Medicine, Vol 60, Iss 1, Pp 282-289 (2024)
Introduction Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of immature myeloid cells. Among the genetic alterations in AML, the RUNX1- RUNX1T1 fusion, resulting from the t (8; 21) (q22; q
Externí odkaz:
https://doaj.org/article/a8afefcf9d974e1a9ddc5d5ce50dca6b
Publikováno v:
Alexandria Journal of Medicine, Vol 60, Iss 1, Pp 259-264 (2024)
Background Acute myeloid leukemia (AML) is a clonal hematopoietic stem cell malignancy characterized by the accumulation of myeloid progenitor cells with arrested differentiation, leading to the suppression of normal hematopoiesis. The disease exhibi
Externí odkaz:
https://doaj.org/article/722ae48307d1464a98a6dc83d9f7fe80
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The tumor microenvironment (TME) plays an important role in the occurrence and progression of Acute Myeloid Leukemia (AML). Single-cell sequencing has enabled researchers to explore the correlation between TME subgroups and tumor prognosis,
Externí odkaz:
https://doaj.org/article/9e79993f16b0463cabc894570976ba2c
Publikováno v:
BMC Pediatrics, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Objective Patients who carry NUP98::NSD1 or FLT3/ITD mutations are reported to have poor prognosis. Previous studies have confidently reported that the poor outcome in younger AML patients is owning to dual NUP98::NSD1 and FLT3/ITD positivit
Externí odkaz:
https://doaj.org/article/705eaaf96dad49d9b9ff5dc7a3c1f11e
Autor:
Sakditad Saowapa, Natchaya Polpichai, Manasawee Tanariyakul, Thanathip Suenghataiphorn, Narathorn Kulthamrongsri, Maireigh McCullough, Mariana Goncalves Damasceno Moreira, Pharit Siladech, Lukman Tijani
Publikováno v:
Hemato, Vol 5, Iss 2, Pp 208-219 (2024)
Background: Autoimmune disorders (ADs) are prevalent among patients with myelodysplastic syndrome (MDS), yet their impact on MDS outcomes, including overall survival (OS), mortality, and transformation to acute myeloid leukemia (AML), is not well def
Externí odkaz:
https://doaj.org/article/caf72f6cfce3483f9dc535d13360fb08
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/adc434aeb1a4406d83975da122237747
Autor:
Shephali Kadam, Atham Ali, Mateusz Pospiech, Sandra Onyemaechi, Yiting Meng, Kanaka Dhuri, J. Andrew MacKay, Houda Alachkar
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 179, Iss , Pp 117265- (2024)
CD99 is a transmembrane protein overexpressed in Acute Myeloid Leukemia (AML), presenting a potential novel therapeutic target. Our group has previously developed anti-CD99-A192 (α-CD99-A192), comprising of single chain variable fragment (scFv) and
Externí odkaz:
https://doaj.org/article/b97cc68ca9dc40bd8b5309fcead456b3
Autor:
Giuseppe Sapienza, Marta Castronovo, Stefania Tringali, Roberto Bono, Cristina Rotolo, Antonino Mulè, Valeria Calafiore, Caterina Patti, Cecilia Agueli, Valentina Randazzo, Alessandra Santoro, Domenica Matranga, Luca Castagna
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionAcute myeloid leukemia (AML) relapse is the main cause of death after allogeneic stem cell transplant (allo-SCT). In AML FLT3+, it was shown that Sorafenib used as maintenance therapy after allo-SCT, significantly reduces the risk of rela
Externí odkaz:
https://doaj.org/article/312b6091ee5e447aba2169519861a944